AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23936562 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivenom treatment
Number of subjects: 120
Study 21806757 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric stain
Number of subjects: 36
Study 21806757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco stain
Number of subjects: 36
Study 21806757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea stain
Number of subjects: 36
Study 21806757 — intervention group
Group type: COMPARATOR
Intervention: Control (no stain)
Number of subjects: 36
Study 19303414 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a (180 microg once weekly)
Number of subjects: 315
Study 19303414 — intervention group
Group type: COMPARATOR
Intervention: lamivudine (100 mg daily)
Number of subjects: 315
Study 16384840 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol 400 IU/day + ascorbic acid 500 mg/day (CEalpha)
Number of subjects: 21
Study 16384840 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR-alpha-tocopherol 290 IU/day + RRR-gamma-tocopherol 130 IU/day + ascorbic acid 500 mg/day (CEalphagamma)
Number of subjects: 21
Study 16384840 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 21
Study 16384840 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 21
Study 14509498 — intervention group
Group type: COMPARATOR
Intervention: Palliative care consultation to primary care physicians (PCPs); educational and supportive services to patients and their families.
Number of subjects: 90
Study 10694559 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy tablets
Number of subjects: 177
Study 10694559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 9424324 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue type plasminogen activator (t‐PA) antigen in urine
Number of subjects: 25
Study 8268142 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and tripotassium dicitrato bismuthate combined with ranitidine and mylanta (58 patients)
Number of subjects: 127
Study 8268142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine and mylanta (40 patients)
Number of subjects: 127
Study 8268142 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor antagonist and antacid (29 patients, H. pylori negative)
Number of subjects: 127
Study 3512820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine irrigation with cefazolin solution
Number of subjects: 0
Study 3512820 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cefazolin administration
Number of subjects: 0
Study 31538829 — intervention group
Group type: EXPERIMENTAL
Intervention: Boneless beef
Number of subjects: 240488
Study 31538829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground beef
Number of subjects: 240488
Study 29994878 — intervention group
Group type: EXPERIMENTAL
Intervention: Open release of the A1 pulley
Number of subjects: 62
Study 29994878 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous release of the A1 pulley
Number of subjects: 62
Study 29994878 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Open and Percutaneous)
Number of subjects: 62
Study 27221771 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat-resveratrol combination (O-R)
Number of subjects: 161
Study 27221771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study 27221771 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 161
Study 27221771 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 161
Study 24581876 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic surgery (SILS)
Number of subjects: 120
Study 24581876 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic appendectomy (LA)
Number of subjects: 120
Study 22386594 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Number of subjects: 1705
Study 22386594 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH (rFSH)
Number of subjects: 1705
Study 20497961 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Bevacizumab (PB)
Number of subjects: 46
Study 20497961 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel + Bevacizumab + Sunitinib (PBS)
Number of subjects: 46
Study 18555944 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-10 numeric rating scale (NRS) for spasticity severity
Number of subjects: 189
Study 16130861 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrian, a self‐etching primer
Number of subjects: 38
Study 16130861 — intervention group
Group type: COMPARATOR
Intervention: One‐Step, a single‐bottle adhesive placed after acid etching
Number of subjects: 38
Study 12382215 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie and high-protein blend formula (HP blend) or commercially available supplement (CNS) post-hemodialysis providing 500 kcal and 15 g protein for 1 month.
Number of subjects: 0
Study 12382215 — intervention group
Group type: COMPARATOR
Intervention: Control group received dietary monitoring and counseling but no specific post-HD supplement.
Number of subjects: 0
Study 12382215 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calorie and high-protein blend formula (HP blend) or commercially available supplement (CNS) post-hemodialysis.
Number of subjects: 0
Study 10584981 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytohemagglutinin (PHA) stimulation in normal pregnancy group (54 women)
Number of subjects: 77
Study 10584981 — intervention group
Group type: COMPARATOR
Intervention: Phytohemagglutinin (PHA) stimulation in RSA group (23 women)
Number of subjects: 77
Study 7604950 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray
Number of subjects: 0
Study 2080707 — intervention group
Group type: COMPARATOR
Intervention: C-0 (no compression, n = 36 patients)
Number of subjects: 100
Study 2080707 — intervention group
Group type: EXPERIMENTAL
Intervention: C-10 (compression for 10 min, n = 32 patients)
Number of subjects: 100
Study 2080707 — intervention group
Group type: EXPERIMENTAL
Intervention: C-20 (compression for 20 min, n = 32 patients)
Number of subjects: 100
Study 2080707 — intervention group
Group type: COMPARATOR
Intervention: C-0 (no compression)
Number of subjects: 100
Study 2080707 — intervention group
Group type: EXPERIMENTAL
Intervention: C-10 and C-20 (compression for 10 and 20 min)
Number of subjects: 100
Study 94266 — intervention group
Group type: EXPERIMENTAL
Intervention: creatinol O‐phosphate (COP) 1020 mg administered i.m. twice a day for 3 days
Number of subjects: 10
Study 94266 — intervention group
Group type: COMPARATOR
Intervention: reference substance (solvent of COP) administered i.m. twice a day for 3 days
Number of subjects: 10
Study 31622732 — intervention group
Group type: EXPERIMENTAL
Intervention: Emibetuzumab + Erlotinib
Number of subjects: 24
Study 31622732 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 24
Study 31622732 — intervention group
Group type: EXPERIMENTAL
Intervention: Emibetuzumab + Erlotinib (in patients with high MET expression)
Number of subjects: 24
Study 31622732 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib (in patients with high MET expression)
Number of subjects: 24
Study 31091683 — intervention group
Group type: EXPERIMENTAL
Intervention: StayingFit online program
Number of subjects: 0
Study 31091683 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28251159 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin group
Number of subjects: 114
Study 28251159 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon group
Number of subjects: 114
Study 28251159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonballoon group
Number of subjects: 114
Study 28251159 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 26059214 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic band exercises for 40 minutes, three times per week for 6 months
Number of subjects: 169
Study 26059214 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 169
Study 23796285 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of inpatient hospital treatment (HOSP)
Number of subjects: 139
Study 23796285 — intervention group
Group type: COMPARATOR
Intervention: 3 days of inpatient treatment followed by 4 days of home treatment by community nurses (early assisted discharge)
Number of subjects: 139
Study 23796285 — intervention group
Group type: COMPARATOR
Intervention: early assisted discharge
Number of subjects: 139
Study 23796285 — intervention group
Group type: EXPERIMENTAL
Intervention: HOSP
Number of subjects: 139
Study 21125215 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 h of NBO plus one HBO session (arm A1)
Number of subjects: 385
Study 21125215 — intervention group
Group type: COMPARATOR
Intervention: 6 h of normobaric oxygen therapy (NBO; arm A0)
Number of subjects: 385
Study 21125215 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 h of NBO plus one HBO session (arm B1)
Number of subjects: 385
Study 21125215 — intervention group
Group type: COMPARATOR
Intervention: 4 h of NBO plus two HBO sessions (arm B2)
Number of subjects: 385
Study 19576325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 300 mg
Number of subjects: 838
Study 19576325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 600 mg
Number of subjects: 838
Study 19576325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg
Number of subjects: 838
Study 19576325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 838
Study 19576325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib (all doses)
Number of subjects: 838
Study 19576325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Number of subjects: 838
Study 19576325 — intervention group
Group type: EXPERIMENTAL
Intervention: Torcetrapib
Number of subjects: 838
Study 17011712 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (0, 8, and 16 mg)
Number of subjects: 20
Study 17011712 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 20
Study 15262902 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril (0.1 mg/kg, 0.3 mg/kg, 0.6 mg/kg)
Number of subjects: 78
Study 15262902 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril
Number of subjects: 78
Study 15262902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 15262902 — intervention group
Group type: COMPARATOR
Intervention: Fosinopril vs Placebo
Number of subjects: 78
Study 11371412 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (180 mg doses over 14 h)
Number of subjects: 0
Study 11371412 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg doses over 36 h)
Number of subjects: 0
Study 11371412 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9267269 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose aprotinin
Number of subjects: 133
Study 9267269 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose aprotinin
Number of subjects: 133
Study 9267269 — intervention group
Group type: COMPARATOR
Intervention: No aprotinin
Number of subjects: 133
Study 8198266 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 10 mg intravenously (i.v.)
Number of subjects: 40
Study 8198266 — intervention group
Group type: COMPARATOR
Intervention: Naloxone 2 micrograms/kg
Number of subjects: 40
Study 3596184 — intervention group
Group type: EXPERIMENTAL
Intervention: YAG laser photocoagulation
Number of subjects: 100
Study 3596184 — intervention group
Group type: COMPARATOR
Intervention: BICAP electrocoagulation
Number of subjects: 100
Study 3596184 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency surgery and mortality
Number of subjects: 100
Study 31247039 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based self-management support program (four group-based interactive sessions)
Number of subjects: 168
Study 31247039 — intervention group
Group type: COMPARATOR
Intervention: Control group (a single educational lecture)
Number of subjects: 168
Study 29909435 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PBMt (Photobiomodulation therapy)
Number of subjects: 18
Study 29909435 — intervention group
Group type: COMPARATOR
Intervention: Placebo PBMt
Number of subjects: 18
Study 25967559 — intervention group
Group type: EXPERIMENTAL
Intervention: O-arm navigation
Number of subjects: 32
Study 25967559 — intervention group
Group type: COMPARATOR
Intervention: Free-hand technique
Number of subjects: 32
Study 25050904 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol treatment
Number of subjects: 24
Study 25050904 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 24
Study 25050904 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRT1 knock down or inhibition
Number of subjects: 24
Study 25050904 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study 21450565 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on prescribing behaviour
Number of subjects: 0
Study 21450565 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 19819469 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg of MgSO(4)
Number of subjects: 99
Study 19819469 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/kg of MgSO(4)
Number of subjects: 99
Study 19819469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 18067438 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (PRECEDE-PROCEED model)
Number of subjects: 104
Study 18067438 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 16037146 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (0.6% end‐tidal isoflurane plus fentanyl)
Number of subjects: 80
Study 16037146 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (1.2% end‐tidal isoflurane plus fentanyl)
Number of subjects: 80
Study 16037146 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (1.8% end‐tidal isoflurane plus fentanyl)
Number of subjects: 80
Study 16037146 — intervention group
Group type: COMPARATOR
Intervention: Group 4 (only isoflurane)
Number of subjects: 80
Study 12453969 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron depletion (three extractions of 500 ml blood at 2-week intervals; group 1A)
Number of subjects: 28
Study 12453969 — intervention group
Group type: COMPARATOR
Intervention: Observation (group 1B)
Number of subjects: 28
Study 10075342 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed MCT-LCT emulsion (n = 7)
Number of subjects: 14
Study 10075342 — intervention group
Group type: COMPARATOR
Intervention: LCT emulsion (n = 7)
Number of subjects: 14
Study 7555551 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (50 to 300 mg three times daily)
Number of subjects: 0
Study 2178677 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilamellar tarsal rotation
Number of subjects: 165
Study 2178677 — intervention group
Group type: COMPARATOR
Intervention: Eversion splinting
Number of subjects: 165
Study 2178677 — intervention group
Group type: COMPARATOR
Intervention: Tarsal advance
Number of subjects: 165
Study 2178677 — intervention group
Group type: COMPARATOR
Intervention: Tarsal grooving
Number of subjects: 165
Study 2178677 — intervention group
Group type: COMPARATOR
Intervention: Tarsal advance and rotation
Number of subjects: 165
Study 2178677 — intervention group
Group type: COMPARATOR
Intervention: Tarsal advance (for lid closure defect)
Number of subjects: 165
Study 7425398 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 18
Study 7425398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 30394326 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic therapy
Number of subjects: 37
Study 30394326 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous dopamine
Number of subjects: 37
Study 30394326 — intervention group
Group type: COMPARATOR
Intervention: Patients with Parkinson's disease (PD)
Number of subjects: 37
Study 29110690 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-engineered cartilage constructed using biomimetic cartilage extracellular‐matrix‐oriented scaffolds combined with autologous chondrocytes
Number of subjects: 100
Study 29110690 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic debridement and microfracture surgery
Number of subjects: 100
Study 25367310 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 68
Study 25367310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 26280726 — intervention group
Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy system (Group MED)
Number of subjects: 32
Study 26280726 — intervention group
Group type: COMPARATOR
Intervention: Anterior open approach (Group AOA)
Number of subjects: 32
Study 22356848 — intervention group
Group type: EXPERIMENTAL
Intervention: Online network of OSH experts (ArboAntwoord)
Number of subjects: 218
Study 22356848 — intervention group
Group type: COMPARATOR
Intervention: Common information sources (control group)
Number of subjects: 218
Study 19473853 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant suture exclusion of the left atrial appendage
Number of subjects: 43
Study 19473853 — intervention group
Group type: COMPARATOR
Intervention: Control group (no left atrial appendage exclusion)
Number of subjects: 43
Study 17322179 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence-enhancing psychosocial interventions
Number of subjects: 0
Study 17322179 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-based interventions
Number of subjects: 0
Study 15086235 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling helmet
Number of subjects: 14
Study 15086235 — intervention group
Group type: COMPARATOR
Intervention: Control (no cooling)
Number of subjects: 14
Study 11800047 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil infusion
Number of subjects: 19
Study 11800047 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine (placebo control) infusion
Number of subjects: 19
Study 9479922 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitored chlorhexidine (CHX) gel treatment (3 x 5 min 1% CHX gel, monitored over 12 weeks)
Number of subjects: 17
Study 9479922 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-day CHX treatment (3 x 5 min 1% CHX gel on two consecutive days)
Number of subjects: 17
Study 7977520 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal nafarelin, 400 micrograms/day
Number of subjects: 75
Study 7977520 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 75
Study 7977520 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal nafarelin
Number of subjects: 75
Study 2537095 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril (10-20 mg/day)
Number of subjects: 14
Study 2537095 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 2537095 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 14
Study 242030 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoston (2 g, taken as two times two pills orally 2 and 5 hrs before tests)
Number of subjects: 15
Study 242030 — intervention group
Group type: COMPARATOR
Intervention: Placebo (taken orally 2 and 5 hrs before tests)
Number of subjects: 15
Study 242030 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoston (2 g)
Number of subjects: 15
Study 31218713 — intervention group
Group type: COMPARATOR
Intervention: Topical glucocorticoids (mometasone furoate, 100 µg in each nostril once daily) and saline irrigation (150 mL twice a day) for 2 weeks
Number of subjects: 0
Study 31218713 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation aerosol therapy composed of essential oils, saline, glucocorticoids, and antibiotics, once daily 5 times per week for 2 weeks
Number of subjects: 0
Study 27668920 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-head 2-thumb encircling technique (OTTT)
Number of subjects: 50
Study 27668920 — intervention group
Group type: COMPARATOR
Intervention: Conventional 2-finger technique (TFT)
Number of subjects: 50
Study 25074688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg twice daily for 24 weeks plus placebo injection every 2 weeks (Arm A)
Number of subjects: 279
Study 25074688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg twice daily for 4 weeks, then 150 mg once daily up to Week 24 plus placebo injection every 2 weeks (Arm B)
Number of subjects: 279
Study 25074688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg twice daily for 4 weeks, then 100 mg once daily up to Week 24 plus placebo injection every 2 weeks (Arm C)
Number of subjects: 279
Study 25074688 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks for 24 weeks plus oral placebo twice daily (Arm D)
Number of subjects: 279
Study 25074688 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo twice daily for 6 weeks, plus placebo injection every 2 weeks, then a switch to arm A or B (Arm E)
Number of subjects: 279
Study 23771400 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical restraint
Number of subjects: 60
Study 23771400 — intervention group
Group type: COMPARATOR
Intervention: Seclusion
Number of subjects: 60
Study 23771400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 21450019 — intervention group
Group type: EXPERIMENTAL
Intervention: Three versus six preoperative cycles of epirubicin/docetaxel + granulocyte colony‐stimulating factor
Number of subjects: 292
Study 21450019 — intervention group
Group type: EXPERIMENTAL
Intervention: SNB after primary chemotherapy
Number of subjects: 292
Study 18640474 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol 1.25 mg q6-8h
Number of subjects: 479
Study 18640474 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol 2.5 mg q1-4h
Number of subjects: 479
Study 18640474 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol
Number of subjects: 479
Study 18640474 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol
Number of subjects: 479
Study 16395181 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification algorithm using physical therapists with varying levels of experience
Number of subjects: 123